GLP-1 Receptor Agonists Should Be Initiated in Patients with Cardiac Murmurs and Native Artery Atherosclerosis
In a patient with a cardiac murmur and native artery atherosclerosis, GLP-1 receptor agonist therapy should be strongly considered and initiated, as the presence of atherosclerotic cardiovascular disease (ASCVD) is a primary indication for these agents, and a cardiac murmur alone does not constitute a contraindication. The cardiovascular benefits—including reduction in major adverse cardiovascular events (MACE), cardiovascular death, and all-cause mortality—far outweigh theoretical concerns in this population 1, 2.
Primary Indication: Atherosclerotic Disease
The 2018 ACC Expert Consensus 1 and 2022 Canadian Cardiovascular Society guidelines 2 explicitly recommend GLP-1 receptor agonists for patients with type 2 diabetes and established ASCVD. Native artery atherosclerosis qualifies as established ASCVD, making this patient a priority candidate for therapy.
Key opportunities to initiate GLP-1RA in your patient include:
- At diagnosis of clinical ASCVD in a patient with type 2 diabetes
- At hospital discharge after an ASCVD-related clinical event
- When not currently on a GLP-1RA or SGLT2 inhibitor with demonstrated CV benefit 1
The evidence shows GLP-1RAs reduce:
- MACE by 12-14% (relative risk reduction)
- All-cause mortality by 12-15%
- Cardiovascular death by 13-15%
- Nonfatal stroke by 16% 2
Recent meta-analyses confirm these benefits are conclusive with high-certainty evidence across 99,599 patients, showing an incidence rate ratio of 0.87 for MACE (NNT = 66) 3.
The Cardiac Murmur: Not a Contraindication
A cardiac murmur is not listed as a contraindication or precaution for GLP-1RA therapy in any guideline. The relevant considerations are:
Actual Contraindications to Assess:
- History of MEN2 or medullary thyroid cancer (absolute contraindication)
- History of pancreatitis (relative contraindication)
- History of gastroparesis (relative contraindication)
- Persistent nausea even at low doses (practical limitation)
- History of proliferative retinopathy (specific concern with semaglutide) 1
What the Murmur Might Indicate:
If the murmur suggests valvular heart disease, this does not preclude GLP-1RA use. In fact, GLP-1RAs demonstrate beneficial effects on:
- Reduced myocardial work and filling pressures
- Pre-/afterload reduction
- Improved endothelial function
- Reduced inflammation and oxidative stress 1, 4
If the murmur is associated with heart failure, the evidence is nuanced:
- GLP-1RAs reduce heart failure hospitalizations by approximately 15% 3
- Benefits are most pronounced in obesity-associated heart failure with preserved ejection fraction (HFpEF) 5
- The cardiovascular benefits in atherosclerotic disease remain robust regardless of heart failure phenotype
Prioritizing GLP-1RA vs SGLT2 Inhibitor
Consider using a GLP-1RA first when priorities include:
- Reducing MACE and CV death (primary goal in ASCVD)
- Substantial weight loss needs
- eGFR consistently <45 mL/min/1.73 m² (GLP-1RAs maintain efficacy; SGLT2i lose glycemic efficacy) 1
- Specific stroke risk reduction (16% relative risk reduction with GLP-1RA vs neutral with SGLT2i) 2
Consider SGLT2 inhibitor first if:
- Concurrent heart failure with reduced ejection fraction
- Significant chronic kidney disease with proteinuria
- Primary goal is preventing heart failure hospitalization (32% relative risk reduction with SGLT2i) 2
Practical Initiation Strategy
Pre-Initiation Assessment:
- Verify no absolute contraindications: MEN2, medullary thyroid cancer history
- Assess renal function: GLP-1RAs remain effective at eGFR <45 mL/min/1.73 m² (unlike SGLT2i)
- Review current glucose-lowering therapy: If on sulfonylurea or insulin, reduce doses prophylactically:
- Sulfonylurea: reduce by 50%
- Basal insulin: reduce by 20% 1
Monitoring During Initiation:
- Gastrointestinal symptoms: Most common adverse effect (63% increase in GI disorders) 3
- Start with lowest dose and titrate slowly
- Educate on transient nausea (typically improves over 4-8 weeks)
- Hypoglycemia surveillance: Especially if on background insulin or sulfonylurea
- Home glucose monitoring: More frequent for first 4 weeks 1
Common Pitfalls to Avoid:
- Do not delay initiation waiting for "optimal" glycemic control—cardiovascular benefits occur independent of A1C reduction 2
- Do not withhold due to concern about the cardiac murmur—no evidence supports this
- Do not forget that hospitalized patients were excluded from most CV outcome trials, so practical data for in-hospital initiation is limited; outpatient initiation is preferred 1
Additional Cardiovascular Benefits Specific to Atherosclerosis
GLP-1RAs function as cardiometabolic substrate-modifying therapies through:
- Reduced atherogenesis
- Upregulated nitric oxide production
- Suppressed NF-κB activation (anti-inflammatory)
- Improved vascular biology and myocardial energetics 1, 5
Recent evidence from the SELECT and SOUL trials demonstrates that 42.5% of non-diabetic patients with established coronary disease who are overweight/obese and 97.9% of diabetic patients ≥50 years with cardiovascular disease meet eligibility criteria for semaglutide therapy 6. Your patient with native artery atherosclerosis clearly falls within this target population.
Safety Profile in Context
While GLP-1RAs increase gastrointestinal (63%) and gallbladder disorders (26%), they reduce:
- Serious adverse events by 9%
- Acute kidney failure by 9%
- Heart failure events by 15%
- Infections by 10% 3
No differences were observed in stroke, pancreatitis, or neoplasm rates compared to controls 3.
The cardiac murmur requires standard cardiovascular evaluation and management, but should not delay or prevent GLP-1RA initiation for the underlying atherosclerotic disease. The proven mortality and MACE reduction in patients with established ASCVD makes GLP-1RA therapy a priority intervention in this clinical scenario.